EyePointEYPT
NASDAQLaboratory Instruments
No cached AI snapshot yet for EYPT.
Be the first to run a multi-agent analysis on this ticker.
Key Stats
214 employees83.43M shares outstandinglisted 2005-01-27
Next earnings ~May 5, 2026
About EyePoint
EyePoint Inc focuses is a clinical-stage biopharmaceutical company committed to developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases, that may reduce the frequency of follow-up care. The company's pipeline program includes i) DURAVYU: a sustained-release product candidate for retinal diseases, with the potential to provide patients with improved visual outcomes with less burden. ii) EYP-2301: early-stage program using Durasert E technology to deliver razuprotafib, a TIE-2 agonist targeting VE-PTP for vascular stability in retinal diseases like wet AMD.
Latest News
Showing market-wide stock news
What history says about longer-term bond yields after the first Fed hike
Global Market: European shares recover as oil rally pauses ahead of Fed decision
How The Fed Has Been Quietly Tightening Ahead Of The Expected Rate Hike
Euro: 1.150 target nears on Fed risk against US Dollar – ING
WTI falls near $100 as Saudi adds Oman route, US stocks surge
Yield on 10-year Treasury hovers above 5% as investors await Fed decision
Related Stocksin Laboratory Instruments
Ready to see the live AI view on EYPT?
Launch a real-time multi-agent room — Claude, GPT, Gemini, DeepSeek, Grok, and Qwen analyzing EYPT side-by-side with live signals.